ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024
May 01 2024 - 7:00AM
ADC Therapeutics to Host First Quarter 2024 Financial Results and
Pipeline Update Conference Call on May 6, 2024
ADC Therapeutics SA (NYSE: ADCT) today announced that it will host
a conference call and live webcast on Monday, May 6, 2024 at 8:30
a.m. EDT to report financial results for the first quarter 2024 and
provide updates on recent progress against key catalysts from the
pipeline.
To access the conference call, please register
here. Registrants will receive the dial-in number and unique PIN.
It is recommended that you join 10 minutes before the event, though
you may pre-register at any time. A live webcast of the call will
be available under “Events and Presentations” in the Investors
section of the ADC Therapeutics website at ir.adctherapeutics.com.
The archived webcast will be available for 30 days following the
call.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a
commercial-stage global leader and pioneer in the field of antibody
drug conjugates (ADCs). The Company is advancing its proprietary
ADC technology to transform the treatment paradigm for patients
with hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA
(loncastuximab tesirine-lpyl) received accelerated approval by the
FDA and conditional approval from the European Commission for the
treatment of relapsed or refractory diffuse large B-cell lymphoma
after two or more lines of systemic therapy. ZYNLONTA is also in
development in combination with other agents and in earlier lines
of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple
ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle),
Switzerland, and has operations in London and New Jersey. For more
information, please visit https://adctherapeutics.com/ and follow
the Company on LinkedIn.
ZYNLONTA® is a registered trademark of ADC
Therapeutics SA.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. In some cases you
can identify forward-looking statements by terminology such as
“may”, “will”, “should”, “would”, “expect”, “intend”, “plan”,
“anticipate”, “believe”, “estimate”, “predict”, “potential”,
“seem”, “seek”, “future”, “continue”, or “appear” or the negative
of these terms or similar expressions, although not all
forward-looking statements contain these identifying words.
Forward-looking statements are subject to certain risks and
uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences
include, but are not limited to: the Company’s ability to achieve
the decrease in total operating expenses for 2024 compared to 2022,
the expected cash runway into 4Q 2025, the effectiveness of the new
commercial go-to-market strategy, competition from new
technologies, and the Company’s ability to grow ZYNLONTA® revenue
in the United States; Swedish Orphan Biovitrum AB (Sobi®) ability
to successfully commercialize ZYNLONTA® in the European Economic
Area and market acceptance, adequate reimbursement coverage, and
future revenue from the same; approval by the NMPA of the BLA for
ZYNLONTA® in China submitted by Overland ADCT BioPharma and future
revenue from the same, our strategic partners’, including
Mitsubishi Tanabe Pharma Corporation, ability to obtain regulatory
approval for ZYNLONTA® in foreign jurisdictions, and the timing and
amount of future revenue and payments to us from such partnerships;
the impact, if any, from data reported by the University of Miami
for their IIT in FL; the timing and results of the Company’s or its
partners’ clinical trials including LOTIS 5 and 7, ADCT 601 and 602
as well as the Company’s early-stage pipeline research projects,
actions by the FDA or foreign regulatory authorities with respect
to the Company’s products or product candidates; projected revenue
and expenses; the Company’s indebtedness, including Healthcare
Royalty Management and Oaktree and Blue Owl facilities, and the
restrictions imposed on the Company’s activities by such
indebtedness, the ability to repay such indebtedness and the
significant cash required to service such indebtedness; and the
Company’s ability to obtain financial and other resources for its
research, development, clinical, and commercial activities.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the “Risk Factors”
section of the Company's Annual Report on Form 20-F and in the
Company's other periodic reports and filings with the Securities
and Exchange Commission. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance, achievements or prospects to be materially
different from any future results, performance, achievements or
prospects expressed in or implied by such forward-looking
statements. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in this
document. The Company undertakes no obligation to revise or update
these forward-looking statements to reflect events or circumstances
after the date of this press release, except as required by
law.
CONTACTS:
Investors and MediaNicole
RileyADC TherapeuticsNicole.Riley@adctherapeutics.com +1
862-926-9040